Table of Contents Table of Contents
Previous Page  677 / 1096 Next Page
Information
Show Menu
Previous Page 677 / 1096 Next Page
Page Background

S661

ESTRO 36

_______________________________________________________________________________________________

differences existed between the AHF and CF groups in

gender, age, clinical stage or histology. A total of 40

patients (78%) had experienced lymph node metastasis

before treatment. Patients received radiotherapy using

AHF in 17 cases and CF in 34 cases. All patients underwent

thoracotomy after induction CRT. The median duration

between the last day of radiotherapy and the day of

operation was 35 days (range, 16–70). The pathologic

complete response (pCR) rates in the primary tumor and

dissected lymph nodes are shown in Table 1. The pCR rates

of adenocarcinoma after induction CRT in the AHF and CF

groups were 41% (7/17) and 24% (8/34) in the primary

tumor and 50% (8/16) and 50% (12/24) in the dissected

lymph nodes, respectively. The pCR rates of SqCC after

CRT in the AHF and CF groups were 75% (6/8) and 29%

(4/14) in the primary tumor and 63% (5/8) and 64% (7/11)

in dissected lymph nodes, respectively. The SqCC in the

primary tumor had significantly higher pCR rates under

AHF compared to CF (p = 0.02). However, the pCR rates of

adenocarcinoma after CRT in the AHF and CF groups were

similar in both the primary tumor and dissected lymph

nodes.

Conclusion

Chemoradiotherapy using AHF may achieve a higher

pathological therapeutic effect than chemoradiotherapy

using CF for squamous cell lung cancer in primary tumors.

EP-1225 Atlas-based segmentation reduces inter-

observer variation and delineation time for OAR in

NSCLC

W. Van Elmpt

1

, J. Van der Stoep

1

, J. Van Soest

1

, T.

Lustberg

1

, M. Gooding

2

, A. Dekker

1

1

MAASTRO Clinic, Department of Radiation Oncology,

Maastricht, The Netherlands

2

Mirada Medical Ltd, Science and Medical Technology,

Oxford, United Kingdom

Purpose or Objective

Tumor and organs-at-risk (OAR) delineations are

considered a major uncertainty in radiotherapy.

Automatic segmentation methods are currently available

that may guide the delineations of OAR. However, the

inter-observer variability in OAR delineations are rarely

studied and the effect of automated methods on

delineation variability has not yet been performed. In this

study we systematically quantified the (reduction of)

inter-observer variation by providing the delineation

expert with an atlas-based generated automatic contour

including time spent on delineations.

Material and Methods

Atlas-based automatic delineations were performed using

commercial available software with an atlas derived for

10 stage I NSCLC patients using institutional delineation

guidelines with minimal anatomical distortions. In a next

step, 20 consecutive prospective stage I-III NSCLC patients

were selected from clinical routine. For these patients, 3

experienced radiation technologists independently

created delineations for heart, mediastinum, spinal cord,

esophagus and brachial plexus according to the

institutional standards. Time taken was also recorded.

Next, the automatic atlas-based contour was provided as

a starting point for a second round of delineations (blinded

for the initial contour). The proposed contour was allowed

to be adapted (or discarded) and modified into a clinical

acceptable contour. The inter-observer variation was

quantified as the non-overlapping volume of the 3

observers for both the initial contours and the adapted

contours. Results are expressed as mean±SD, p-values

calculated using a Wilcoxon test.

Results

Comparing the initial contours with the proposed atlas-

generated contour, the inter-observer variation volumes

reduced significantly for the mediastinum: 253±93 cm

3

to

168±103 cm

3

(p<0.01), spinal cord: 32±10 cm

3

to 17±3 cm

3

(p<0.01) and heart: 211±69cm

3

to 136±72 cm

3

(p<0.01).

For the esophagus there was no reduction inter-observer

variation volume (p=0.601), also no clinically significant

differences for brachial plexus were observed: 12.9±5.4

cm

3

vs 12.2±5.1cm

3

. The average delineation time for the

above structures was reduced from 18.1±4.8 to 13.2±5.5

minutes (p<0.01), mainly dominated by the reduction in

time needed for the mediastinal delineation and heart.

Conclusion

Besides a reduction in contouring time, the inter-observer

variation is also reduced if an atlas-based segmentation

approach is used as the initial starting point for

delineations. Especially for the larger structures such as

the heart and mediastinum the impact on time gain and

increase of quality is significant.

EP-1226 Stereotactic robotic body radiotherapy for

patients with pulmonary oligometastases

P. Berkovic

1

, A. Gulyban

1

, L. Swenen

1

, D. Dechambre

1

, P.

Viet Nguyen

1

, N. Jansen

1

, C. Mievis

1

, N. Bartelemy

1

, P.

Lovinfosse

1

, M. Baré

1

, F. Lakosi

2

, L. Janvary

3

, P.A.

Coucke

1

1

C.H.U. - Sart Tilman, Radiotherapy department, Liège,

Belgium

2

Health Science Center- University of Kaposvar,

Radiation Oncology, Kaposvar, Hungary

3

University of Debrecen - Medical Center, Onco

logy Clinic, Debrecen, Hungary

Purpose or Objective

To analyse local control (LC), pulmonary and distant

progression free survival (pulmonary PFS, DFS), overall

survival (OS) and toxicity in a cohort of patients treated

by stereotactic body radiotherapy (SBRT) for

oligometastatic pulmonary lesions. To evaluate the

potential influence of age, histology, controlled primary,

performance status, biological effective dose (BED) and

other parameters on the obtained results.

Material and Methods

Consecutive patients with up to 3 synchronous lung

metastases were included in this study for Cyberknife at

the Liege University Hospital. All patients were referred

for stereotactic treatment after a full staging including

baseline registration of the pulmonary function, chest and

abdominal diagnostic computed tomography (CT) and

[18F]-fluorodeoxyglucose (FDG) positron emission

tomography (PET)-CT imaging confirming the presence or

absence of tumoral activity at the primary tumour site and

extra-pulmonary metastases. The intended prescription

dose was 60 Gy in 3 fractions, prescribed on the 80%

isodose line and adapted based on clinical risk-factors.

Local control (LC), lung and distant progression free

survival (lung and distant PFS) and overall survival (OS) of

patients were generated using Kaplan-Meier survival

curves. Age, gender, performance status (PS), primary

histology, controlled primary as patient specific, while